1	Pertussis upsurge, age shift and vaccine escape post-COVID-19 caused by <i>ptxP3</i>
2	macrolide-resistant Bordetella pertussis MT28 clone in China: a genomic
3	epidemiology study
4	
5	Pan Fu <sup>a,b,1</sup> , Gangfen Yan <sup>c,1</sup> , Yijia Li <sup>a</sup> , Li Xie <sup>d</sup> , Yuehua Ke <sup>e</sup> , Shuxiang Qiu <sup>f</sup> , Shuang
6	Wu <sup>f</sup> , Xiaolu Shi <sup>f</sup> , Jie Qin <sup>a</sup> , Jinlan Zhou <sup>c</sup> , Guoping Lu <sup>c*</sup> , Chao Yang <sup>d*</sup> , Chuanqing
7	Wang <sup>a,b*</sup>
8	
9	<sup>a.</sup> Laboratory of Microbiology, Department of Clinical Laboratory, Children's Hospital
10	of Fudan University, National Children's Medical Center, Shanghai, China
11	<sup>b.</sup> Nosocomial Infection Control Department, Children's Hospital of Fudan University,
12	National Children's Medical Center, Shanghai, China
13	<sup>c.</sup> Pediatric Intensive Care Unit, Children's Hospital of Fudan University, National
14	Children's Medical Center, Shanghai, China
15	<sup>d</sup> The Center for Microbes, Development and Health, CAS Key Laboratory of
16	Molecular Virology and Immunology, Shanghai Institute of Immunity and Infection,
17	Chinese Academy of Sciences, Shanghai, China
18	<sup>e</sup> Department of Bacteriology, Capital Institute of Pediatrics, Beijing, China
19	<sup>f</sup> Shenzhen Center for Disease Control and Prevention, Shenzhen, China
20	<sup>1</sup> Those authors contribute equally
21	
22	*Correspondence
23	Chuanqing Wang, Email: <u>chuanqing523@163.com.</u>
24	Chao Yang, Email: cyang@siii.cas.cn
25	Guoping Lu, Email: lgp@fudan.edu.cn
26	

### 27 Summary

### 28 Background

The upsurge of pertussis post-COVID-19 and expansion of macrolide-resistant *Bordetella pertussis* (MRBP) pose significant public health challenges worldwide. China has experienced notable pertussis upsurge post-COVID-19, alongside an age shift to older children, vaccine escape and a notable rise in MRBP prevalence. We describe the genomic epidemiological investigation of these events.

34

## 35 Method

We did a retrospective, population-based study using culture-positive *B. pertussis* from Children's Hospital of Fudan University (CHFU), the exclusive referral hospital for childhood notifiable infectious diseases, in Shanghai, China between June 2016 and March 2024. We analysed strain and pertussis epidemiology dynamics by integrating whole-genome sequencing of 723 strains with antimicrobial susceptibility, transcriptomic proflie, and clinical data. We compared the genome sequences of Shanghai strains with 6450 Chinese and global strains.

43

## 44 Findings

45 Coincident with national situation, pertussis cases upsurged post-COVID-19 in Shanghai. At CHFU, the number of confirmed cases (n=349) in the first three months 46 47 of 2024 exceeded the total case of previously years ( $n \le 177$ ). Post-COVID-19, patients shifted from predominantly infants (90%, 397/442) to widespread infection among 48 older children (infant: 16%, 132/844), with vaccinated individuals surging from 31% 49 (107/340) to 88% (664/756); MRBP prevalence increased from 60% (267/447) to 98% 50 51 (830/845). The emergence and expansion of a *ptxP3*-linage, macrolide-resistant novel 52 clone with MLVA type 28, MR-MT28, uniquely capable of causing substantial 53 infections among older children and vaccinated individuals, temporally strongly 54 associated with the pertussis upsurge and epidemiological transition. MR-MT28 exhibited increased expression of antigen genes including pertussis toxin genes, along 55 with high incidence of abnormal C-reactive protein, but associated with significantly 56 57 milder clinical symtoms (e.g. wheezing, facial blushing, p < 0.01), higher proportion of normal chest computed tomography (p < 0.05) and lower hospitalization rate (p < 0.01). 58 59 Phylogenomic clustering analysis revealed a higher proportion of MR-MT28 strains 60 grouping into clusters representing putative transmission. We reconstructed the evolutionary history of MR-MT28, and showed that it most likely originated in China 61 around 2016 (95% highest probability density: 2013-2017) after acquiring several 62 63 mutations, including a novel antigen allele prn150 and 23S rRNA A2047G mutation. 64 Approximately one quarter (26%, 50/195) of MR-MT28 has evolved into predicted PRN-deficient strains. MR-MT28 has been identified in four regions (Anhui, 65 66 Shanghai, Beijing and Guangdong) of China and continuously detected in Shanghai and Beijing, suggesting domestic spread and colonization. 67

68

#### 69 Interpretation

70 We identified a *ptxP3*-linage, macrolide-resistant novel clone, MR-MT28, and provide

evidence that pathogen evolution is more likely the primary factor driving pertussis upsurge, age shift and vaccine escape. MR-MT28 potentially poses a high global spread risk and warrants global surveillance. Macrolides may no longer be suitable as first-line drugs for pertussis treatment in China.

75

## 76 Funding

National Key Research and Development Program of China (2021YFC2701800 and
2022YFC2304700), National Natural Science Foundation of China (82202567 and
32270003), Youth Innovation Promotion Association, Chinese Academy of Sciences
(2022278), Shanghai Rising-Star Program (23QA1410500), and Shanghai municipal
three-year action plan for strengthening the construction of the public health system
(2023-2025) GWVI-2.1.2.

83

84 **Key words:** pertussis, *Bordetella pertussis*, age shift, vaccine escape, 85 macrolide-resistant, MT28

86

87

## 88 Research in context

## 89 Evidence before this study

In the first two months of 2024, an unexpected upsurge in pertussis was seen in both 90 91 China and Europe. Furthermore, the pertussis upsurge in China exhibited atypical patterns, including an age shift to older children, vaccine escape and a notable 92 93 increase in macrolide-resistant Bordetella pertussis (MRBP) prevalence. We aimed to test the hypothesis linking pertussis upsurge and epidemiological transition to 94 95 pathogen evolution. We searched PubMed for molecular epidemiology studies of macrolide-resistant Bordetella pertussis using the terms ("Bordetella pertussis" OR 96 97 "pertussis" OR "whooping cough") AND ("macrolide resistant" OR "erythromycin 98 resistant") for articles before March 2024 and identified 40 studies. MRBP has been 99 reported in eight counties, including United States, United Kingdom, France, Iran, 100 Cambodia, Vietnam, Japan and China. While MRBP incidence in other countries 101 remained low, it was notably high in China, accounting for 50% and even 90% of strains across various regions. The risk of MRBP spreading out of China was 102 103 previously considered low, primarily because Chinese strains predominantly belonged 104 to ptxP1-lineage, whereas the globally prevalent lineage was ptxP3. However, the 105 situation is changing, as *ptxP3*-MRBP strains have been identified in multiple regions of China since 2017. In Shanghai, we identified a sharply increase of *ptxP3*-MRBP 106 107 prevalence post-COVID-19, coinciding with pertussis age shift to older children and 108 vaccine escape. A similar scenario was independently observed in Beijing. 109 Additionally, there is a significant rise in pertussis cases since the beginning of 2024. 110 Currently, there is a lack of study testing the link between pertussis upsurge, epidemiological transition, and the evolution of its causative pathogen. 111

112

## 113 Added value of this study

114 Our study identified a *ptxP3*-linage, macrolide-resistant novel clone, MR-MT28,

115 which is uniquely capable of causing substantial infections among older children and 116 vaccinated population, suggesting enhanced vaccine escape. The emergence and rapid 117 expansion of MR-MT28 temporally strongly associated with the upsurge of pertussis 118 cases, age shift, vaccine escape and notable rise in MRBP prevalence. MR-MT28 was 119 characterized by increased expression of antigen genes long with high incidence of 120 abnormal C-reactive protein, but associated with significantly milder clinical sytmptoms, which may prolong the interval before seeking medical care, thereby 121 122 amplifying transmission opportunities. Phylogenomic clustering analysis indicated 123 that MR-MT28 may have increased transmissibility. Therefore, MR-MT28 may have 124 competitive advantages due to antimicrobial resistance, enhanced vaccine escape, 125 increased opportunities for transmission and transmissibility. We reconstructed the 126 evolutionary history of MR-MT28 and showed that it most likely originated in China 127 around 2016 after the acquisition of several mutations, and COVID-19 may have 128 promoted its expansion. Approximately one quarter of MR-MT28 strains has evolved 129 into predicted PRN-deficient strains. Our results showed the domestic spread and 130 colonization of MR-MT28.

131

### 132 Implications of all the available evidence

Our study provides evidence that pathogen evolution, rather than the widely accepted notion of wanning immunity or 'immunity debt', is more likely the primary factor driving pertussis upsurge, age shift and vaccine escape. MR-MT28 potentially poses a high global spread risk, due to its consistent ptxP3 allele and epidemiology across many counties, together with resistance to first-line drugs and potentially competitive advantages, which warrants global surveillance and research efforts. Macrolides may no longer be suitable as first-line drugs for pertussis treatment in China.

- 140
- 141

#### 142 Introduction

Pertussis (whooping cough) is a highly contagious disease primarily caused by 143 Bordetella pertussis. The introduction of the whole-cell vaccines (WCVs) in the 144 145 1950s, and the switch to acellular vaccines (ACVs) in the 1980–1990s, significantly reduced pertussis disease burden.<sup>1</sup> However, the resurge of pertussis has been reported 146 globally during the past two decades.<sup>2-5</sup> The burden of pertussis is still high, with an 147 estimated 24 million cases and 160,700 deaths in children younger than five years in 148 2014.<sup>6</sup> In China, ACV was applied since 2007 and completely replaced WCV in 2012. 149 Despite over 99% vaccine coverage among children, the numbers of reported 150 pertussis cases sharply increased from <3,000 per year in 2006–2013 to 30,027 in 151 2019.7 A reduced incidence of pertussis has been reported in children since the 152 beginning of the COVID-19 pandemic, due to the non-pharmaceutical interventions.<sup>8,9</sup> 153 However, the recent upsurge in pertussis post-COVID-19 restrictions have been 154 documented in China and Europe.<sup>10-14</sup> In China, the number of pertussis cases 155 reported in the first two months of 2024 (32,380 cases) was >20 times higher than 156 157 during the same periods in previous years, approaching the total cases reported for the entire year of 2023 (38,205 cases).<sup>10,11</sup> 158

159

Pertussis resurge has been attributed to various factors, including wanning immunity, 160 improved diagnostics, and *B. pertussis* evolution.<sup>2-5</sup> The importance of *B. pertussis* 161 evolution is suggested by the antigenic divergence between circulating strains and 162 vaccine strains. Sequence divergence has been identified in several genes encoding 163 ACV antigens or their promotor, including filamentous hemagglutinin (Fha), pertactin 164 (Prn), fimbriae (Fim), pertussis toxin (Ptx) and its promoter (*ptxP*).<sup>15</sup> *ptxP3* strains are 165 currently dominating infections in most of the high-income countries, probably due to 166 their higher virulence caused by more Ptx production.<sup>16</sup> Moreover, Prn-deficient 167 strains which confer fitness advantages particular to ACV vaccinated populations, 168 have been increasingly reported and became dominant in multiple countries such as 169 Unite States and Australia.<sup>17</sup> Besides *B. pertussis* evolution toward vaccine escape, the 170 emergence of macrolide-resistant B. pertussis (MRBP) mediated by A2047G mutation 171 172 in the 23s rRNA gene, which confers resistance to first-line drugs such as erythromycin and azithromycin for pertussis treatment, posed further public health 173 issues.<sup>18</sup> 174

175

176 The circulating *B. pertussis* stains and pertussis epidemiology in China differ significantly from those in other countries. ptxP1 strains have been predominant in 177 China until 2019,  $^{19-21}$  rather than globally prevalent *ptxP3* strains. Moreover, the 178 incidence of MRBP in China is notably high, accounting for over 50% and even 90% 179 of strains in various regions,<sup>21–24</sup> while MRBP remains rare in other countries. Since 180 Chinese MRBP strains were predominantly *ptxP1*, their risk of spreading out of China 181 was previously considered low. Additionally, pertussis patients in China were 182 primarily identified in infants less than one year old,<sup>25</sup> unlike the other countries 183 where resurgence of pertussis was more observed in older children and 184 adolescents/adults.<sup>4,5</sup> However, the situation in China is changing, as *ptxP3*-MRBP 185

strains have been identified in multiple regions of China since 2017.<sup>21–24</sup> In Shanghai, 186 we previously reported that *ptxP3*-MRBP had replaced *ptxP1* strains and dominated 187 infections after 2020, with a substantially increased infections in older, vaccinated 188 children.<sup>22,23</sup> Similar situation was recently identified in Beijing. During 2021-2022, 189 ptxP3-MRBP accounted for 78.8% patients, and the proportion of patients in children 190 over three years old doubled than before.<sup>24</sup> The *ptxP3*-MRBP potentially poses a high 191 global spread risk because its consistent *ptxP3* allele and epidemiology across many 192 193 counties.

194

195 Coincident with national situation, pertussis cases upsurged post-COVID-19 in 196 Shanghai. We have carried out continuous surveillance of B. pertussis stains and 197 pertussis in Shanghai since 2016, and obtained strains and corresponding clinical data 198 covering the transition period pre- and post-COVID-19. We previously described the genotype dynamics of ptxP3-MRBP based on a subset of strains by multi-locus 199 variable-number tandem-repeat analysis (MLVA)<sup>22,23</sup> Compared with traditional 200 typing methods such as MLVA, whole-genome sequencing (WGS) provides finer 201 202 resolution and more comprehensive information including virulence and antimicrobial 203 genes. In this study, we took advantages of WGS and sequenced culture-positive B. 204 *pertussis* stains between June 2016 and March 2024. By combining with phenotypic, 205 transcriptomic, and clinical data, we aim to investigate the link between pertussis upsurge, epidemiological transition, and *B. pertussis* evolution. We further compared 206 207 Shanghai strains with Chinese and global strains to investigate its domestic and global 208 spread risk.

209

### 210 Methods

#### 211 Isolates sampling and participants

212 Pertussis is a notifiable disease in China. We did a retrospective, population-based 213 study in Shanghai, the most populous city in China, and enrolled pertussis patients 214 from Children's Hospital of Fudan University (CHFU), the exclusive referral hospital 215 for childhood notifiable infectious diseases. The nasopharyngeal swab samples of 216 patients with suspected pertussis infection are collected and delivered to microbiology 217 laboratory. Pertussis patients were defined as positive culture and/or PCR testing, or 218 showed typical clinical symptoms of pertussis. We studied culture-positive B. 219 pertussis between June 2016 and March 2024 (all the culture-positive strains beween 220 June 2016 and August 2023, and randomly selected strains between September 2023 221 and March 2024, appendix p 2). The laboratory testing results and clinical data were 222 extracted from medical records and all data analysis was anonymous. For comparison, 223 we also included the genomes of 11 randomly selected strains (appendix p 12) 224 collected after 2019 in Beijing (n=8, from Capital Institute of Pediatrics, 2019-2022) 225 and Shenzhen, Guangdong (n=3, from Shenzhen Center for Disease Control and Prevention, 2023). The study protocol was approved by the Ethics Committee of the 226 227 CHFU (No. 2022-66).

228

#### 229 Whole-genome sequencing and analysis

230 Genomic DNA of B. pertussis strains were extracted using QIAamp DNA mini kit 231 (QIAGEN) and whole-genome sequencing were performed on Illumina NovaSeq 232 platform. Sequencing data were strictly trimmed and analyzed as previously described.<sup>26</sup> Briefly, species identification based on sequencing data were performed 233 using Kraken 2. Core-genome single-nucleotide-polymorphisms (SNPs) were 234 235 identified using the Snippy pipeline. Maximum-likelihood phylogenetic trees were 236 constructed using RAxML-NG based on core-genome SNPs. Genome assembly was 237 preformed using shovill pipeline. Assembled sequences were used for vaccine antigen typing by searching against BIGSdb-Pasteur genomic platform for Bordetella.<sup>27</sup> Dated 238 phylogeny and population size dynamics were analyzed using BEAST 1.10 with 239 240 Skygrid coalescent model. We performed pangenome-level analysis to identified 241 lineage/clone-specific genomic variations, including SNPs, gene presence/absence 242 and unitigs using unitig-caller and pyseer. A total of 6439 publicly available genome 243 from 34 countries and six continents were downloaded from NCBI GenBank or SRA 244 database, with accession numbers listed in the appendix (appendix p 13).

245

## 246 MLVA and antimicrobial susceptibility testing

Multiple locus variable-number tandem repeat analysis (MLVA) was performed as described by Schouls et al.<sup>28</sup> The minimum inhibitory concentrations (MICs) of four antimicrobial agents were determined by the E-test. The standardized interpretation criteria are based on our previous report.<sup>22</sup>

251

#### 252 Transcriptomic analysis and quantification of antigen gene expression

The RNA of *B. pertussis* strains was extracted using QIANGEN RNA extraction kit (TIANGEN BIOTECH, Beijing, China). cDNA library construction and sequencing were performed on Illumina NovaSeq platform at Novogene Co. Ltd. (Beijing, China). Differentially expressed genes identification and pathway enrichment analysis were performed using R packages DESeq2 and ClusterProfiler. Transcriptomic and genomic sequencing data have been deposited in the NCBI Sequence Read Archive (SRA) under accession number PRJNA1071282.

260

261 To quantify antigen gene expression level, reverse transcription was conducted using YEASEN cDNA Synthesis SuperMix for qPCR kit (Yeasen Biotechnology, Shanghai, 262 263 China). Amplifications of virulence genes were performed using the Applied 264 Biosystems QuantStudioTM 5 Real-Time qPCR system (ThermoFisher SCIENTIFIC, Waltham, MA, US), with initial denaturation for 5 min at 94 °C, and 35 cycles at 265 266 94 °C for 30 s, annealing for 30 s at 52 °C, followed by elongation at 72 °C for 30 s, 267 and a final step at 72 °C for 5 min. The presence of gene specific amplicons was 268 verified visually by 2% agarose gel electrophoresis using Glodview staining. B. 269 *pertussis* ATCC9797 was used as the reference strain and the house-keeping gene tyrB 270 was used as the reference gene. The virulence gene expressions were calculated by the comparative CT method ( $2^{-\Delta\Delta CT}$ ). 271

272

#### 273 Statistical analysis

Datasets were compared with Chi-squared tests for categorical data and
Mann-Whitney test for continuous data using GraphPad Prism 9. *P*-values less than
0.05 were considered statistically significant.

277

## 278 Role of the funding source

The funding sources for this study had no role in the study design, data collection, data analysis, data interpretation, or writing of the manuscript. The corresponding author had full access to all the data in the study and has final responsibility for the decision to submit this manuscript for publication.

283

## 284 **Results**

285 Coincident with national situation, pertussis cases upsurged post-COVID-19 in 286 Shanghai (appendix p 1). From June 2016 to March 2024, a total of 2659 patients 287 were diagnosed with pertussis in CHFU. Among these, 1479 (56%) patients were 288 confirmed by positive strain cultures, while the others were diagnosed by positive 289 PCR-detection or showed typical pertussis symptoms. We enrolled all the 290 culture-positive *B. pertussis* strains beween June 2016 and August 2023 (n=714), and 291 100 randomly selected strains (13% culture-positive strains) between September 2023 292 and March 2024. A total of 712 (87%) enrolled culture-positive strains were 293 successfully sequenced and identified as *B. pertussis*. The remaining were identified 294 as other *Bordetella* (n=4) or no longer viable (n=98). Of the 712 patients, 678 (95%) 295 were children patients and the remaining were households. Among children patients 296 with available clinical and vaccination data (table 1), 68% (458/672) were infants 297 (aged  $\leq 1y$ ), 46% (310/674) were female, and 52% (284/546) had been vaccinated. A 298 total of 507 (71%) sequenced strains were MRBP, which are resistant to erythromycin, 299 clarithromycin, azithromycin and but all were susceptible to 300 sulfamethoxazole/trimethoprim. All MRBP strains carried the 23S rRNA A2047G 301 mutation.

302

Two phases of pertussis epidemic were identified in Shanghai, with the emergence of COVID-19 as transition point (figure 1). From pre- (n=447) to post-COVID-19 (n=845), the proportion of MRBP infections in children increased from 60% to 98%. Moreover, patients shifted from being dominant by infants (90%, 397/442) to widespread infection among older children (infant: 16%, 132/844), with a notable increase in the proportion of vaccinated population, surging from 31% (107/340) to 88% (664/756).

310

To characterize the circulating *B. pertussis* lineages, we constructed a phylogenic tree of 712 Shanghai strains based on core-genome SNPs (figure 2A). Two lineages were identified, which were designated as *ptxP1*- and *ptxP3*-lineage based on *ptxP* alleles. Nearly all (98%, 313/321) *ptxP1*-lineage strains and 50% (194/391) *ptxP3*-lineage strains were MRBP.

316

317 Within *ptxP3*-lineage, all MRBP strains and one MSBP strain clustered together and

318 belonged to a specific clone with MLVA type 28 (MT28), which was designed as 319 MR-MT28. A novel antigen allele prn150, with one synonymous mutation (C531T) 320 compared with prn2, was identified in MR-MT28. The prn of 26% (50/195) 321 MR-MT28 strains were predicted to be PRN-deficient. The genotypes of MR-MT28 322 were *ptxP3/prn150* or PRN-deficient /*fhaB1/ptxC2/ptxA1/firm2-1/fim3-1*. Except 323 MR-MT28, all other MT28 strains were MSBP and designated as MS-MT28, which is 324 closely related to MR-MT28 on the phylogenic tree (figure 2A). Non-MT28 strains of 325 *ptxP3*-lineage was designated as *ptxP3*-other.

326

327 The emergence and expansion of MR-MT28 temporally strongly correlated with the 328 transition of pertussis epidemiology and upsurge of cases (table 1 and figure 2B). 329 Post-COVID-19, MR-MT28 proportion increased sharply and dominated infections 330 since 2022. The proportion of *prn150* or PRN-deficient strains kept increasing alongside the expansion of MR-MT28. Notably, MR-MT28 uniquely caused 331 332 widespread infection among older children (infant: 25%, 47/189) and accounted for a 333 substantial proportion (87%, 150/172) of infections among vaccinated population. In 334 contrast, other types predominantly infected infants ( $\geq 83\%$ ), with a much lower 335 proportion of infections among vaccinated population ( $\leq$ 39%).

336

337 Increased transmission may contribute to the expansion of MR-MT28. To investigate 338 this possibility, genomic clustering analysis based on SNP-distance was performed to 339 infer putative transmissions. Strains from patient-household pairs were most likely 340 from recent transmission. There was no SNP between strains from 30 (90%) of 33 patient-household pairs, which were consistent with recent transmission, while the 341 342 remaining three pairs had 32 or more SNPs. We therefore selected zero SNP difference as the cutoff to infer genomic cluster representing putative transmission. 51% 343 344 (96/190) MR-MT28 strains were assigned into genomic clusters, which was higher 345 than other types and significantly (p < 0.01) higher than ptxP1 and ptxP3-other (figure 346 2C), indicating a potentially increased transmissibility of MR-MT28.

347

348 We randomly selected eight strains (MR-MT28: n=3, MS-MT28: n=3, *ptxP3*-other: 349 n=2) for transcriptomic sequencing to investigate the possible molecular mechanism 350 of MR-MT28 expansion. We found substantial differences of transcriptomic profiles 351 between MT-28 (MR-MT28 and MS-MT28) and *ptxP3*-other strains (figure 3A), with 352 879 differentially expressed genes (DEGs) identified (appendix p 163). Enrichment 353 analysis of DEGs indicated that virulence-related pathways including bacterial 354 secretion system (ko03070) and pertussis (ko05133) were significantly (p < 0.01) 355 up-regulated (fold change >2) and bacterial motility proteins pathway was 356 significantly downregulated (fold change <-2) in MT-28 strains. More specifically, 357 most antigen genes were significantly upregulated, including Ptx encoding genes (*ptxA* to *ptxE*). There was limited difference of transcriptomic profiles between 358 359 MR-MT28 and MS-MT28, with only eight DEGs not associated with known 360 virulence or antigen genes identified (figure 3B).

361

To validate gene expression results, we further quantified the expression of *ptxA* and *prn* of 40 strains (ten randomly selected strains per type) by quantitative PCR (qPCR, figure 3C). Consistent with transcriptomic analysis, the expression levels of *ptxA* in MT28 strains were significantly (p<0.01) higher than *ptxP3*-other strains and higher than *ptxP1*-lineage strains (p=0.06). There is no significant difference in the expression of *ptxA* and *prn* between MR-MT28 and MS-MT28 under the growth conditions tested, despite MR-MT28 carrying a novel *prn* allele.

369

370 In line with increased expression of Ptx encoding genes, the incidence of abnormal 371 C-reactive protein (CRP) associated with MR-MT28 (20%) was significantly higher 372 than ptxP1-lineage (8%) and ptxP3-other (9%), and higher than MS-MT28 (5%, 373 p=0.089). However, overall, MR-MT28 infection caused milder clinical symptoms 374 (table 1), including spasmodic cough, wheezing, sputum production, facial blushing and post-tussive vomiting, which were significantly (p < 0.01 or 0.05) milder for 375 376 MR-MT28 than other types. Moreover, MR-MT28 infections exhibited a significantly 377 (p < 0.05) higher proportion of normal chest computed tomography results and a 378 significantly (p < 0.01) lower hospitalization rate. Clinical symptoms among patients 379 with same age catogory or vaccination status showed showed similar trends (appendix 380 p1).

381

To investigate the origin and spread of MR-MT28 in China and globe, we newly sequenced 11 Beijing and Guangdong strains between 2019 and 2023, and compared with 6439 global strains. Phylogenetic analysis showed that MT28 clone existed in multiple regions worldwide, but so far, MR-MT28 was exclusively identified in China (figure 4A, B).

387

388 The MT28 clone was not a recently emerged one and likely originated from Europe 389 around 2003 (95% highest probability density [HPD]: 1999-2006, figure 3B). It has 390 spread in Europe and United States and was inferred to introduce to China around 391 2007 (95% HPD: 2005-2011). There are only two SNPs between MR-MT28 and 392 MS-MT28 strains: 23S rRNA A2047G mutation and BP0685 (dehydrogenase/oxidase) 393 G15951A synonymous mutation. The *prn150* was not only identified in MR-MT28, 394 but also found in a MS-MT28 strain closely related to MR-MT28 (figure 2A, 4B). 395 After the acquisition of prn150, BP0685 G15951A mutation and 23S rRNA A2047G mutation, MR-MT28 most likely originated in China in 2016 (95% HPD: 2013-2017), 396 one year prior to the first report of MR-MT28 strain in Anhui, China in 2017.<sup>21</sup> 397 398 Notably, a sub-clone of MR-MT28 evolved into predicted PRN-deficient around 2019 399 (95% HPD: 2017-2019). Now MR-MT28 has been identified in four regions of China, 400 including Anhui, Shanghai, Beijing and Guangdong (figure 4B). Beyond Shanghai, 401 continuously identification of MR-MT28 occurred in Beijing during 2019-2022, 402 indicating that domestic spread and colonization has occurred.

403

The effective population size of MT28 clone has steadily increase since its introduction into China (figure 4C). Intriguingly, following the origination of MR-MT28 in 2016, the overall population size did not increase but instead declined
until the advent of COVID-19. Post-COVID-19, MR-MT28 population size increased
rapidly, indicating that COVID-19 might be a critical factor for its rapid expansion.

409

## 410 Discussion

411 The continuous surveillance and sampling in Shanghai provide a valuable opportunity 412 to comprehensively investigate the link between pertussis upsurge, epidemiological 413 transition, and *B. pertussis* evolution. Though the integration of large-scale WGS with 414 phenotypic, transcriptomic, and clinical data, we identified and characterized a novel 415 ptxP3-linage, macrolide-resistant clone, MR-MT28, which accounted for a substantial 416 proportion of infections in older children and vaccinated individuals. The emergence 417 and rapid expansion of MR-MT28 temporally strongly associated with pertussis upsurge, age shift, vaccine escape and sharp increase in MRBP prevalence. 418

419

420 While previous reports have noted pertussis age shift to older children and adolescents and vaccine escape,<sup>4,5</sup> the situation in Shanghai exhibits distinct features. First, unlike 421 gradual shifts observed in most countries, the shift in Shanghai occurred very quickly. 422 423 Within two years, the proportion of older children (>1y) and vaccinated individuals surged from 10% and 31% to 84% and 88%, respectively, with the emergence of 424 425 COVID-19 as the transition point. Second, pertussis shift in other countries was 426 generally associated with the expansion of more virulent ptxP3 strains, resulting in more severe clinical symptoms and higher hospitalization rates<sup>16</sup>. However, although 427 MR-MT28 exhibited increased ptxA expression levels and higher incidence of 428 429 abnormal CRP, it has been associated with generally milder clinical symptoms and a 430 low hospitalization rate. Third, whereas the circulating ptxP3-lineage in most 431 countries was polyphyletic with multiple subtypes and no dominant clone reported, a 432 single clone, MR-MT28, dominated infections in Shanghai post-COVID-19 and has 433 spread to multiple regions of China.

434

The causes of pertussis upsurge, age shift and vaccine escape have been attributed to 435 multiple factors, including wanning immunity, 'immunity debt',<sup>9</sup> improved 436 diagnostics and pathogen evolution, with the first two being considered as the primary 437 factors. <sup>2–5</sup> While wanning immunity or 'immunity debt' could explain the increased 438 incidence among older children and upsurge of cases, it should not affect B. pertussis 439 440 population composition and dynamics, and cannot explain the observation of MR-MT28 replacing other lineages and dominating infections. Improved diagnostics 441 442 similarly do not affect B. pertussis population dynamics, and our results are based 443 cultured strains, which are independent of diagnostic methods. Moreover, independent observations in Beijing<sup>24</sup> provide further evidence that this scenario is not a bias 444 caused by diagnostics. 445

446

447 We proposed that pathogen evolution is more likely the primary factor driving the 448 scenario in Shanghai and China. MR-MT28 is uniquely capable of causing a 449 substantial proportion of infections among older children and vaccinated individuals, 450 suggesting enhanced vaccine escape. Moreover, the relatively milder clinical 451 symptoms may prolong the interval before seeking medical care, thereby amplifying 452 transmission opportunities. Phylogenomic clustering analysis provided evidence for 453 the increased transmissibility of MR-MT28. Consequently, MR-MT28 may have 454 competitive advantages due to antimicrobial resistance, enhanced vaccine escape, 455 increased opportunities for transmission and transmissibility. In addition, the effective 456 population size of MR-MT28 increased rapidly post-COVID-19, which could be related to the increased family contacts, particularly with unvaccinated infants, the 457 major source for pertussis transmission,<sup>29</sup> due to long-term lockdown and home life. 458 These factors combined may have promoted the rapid expansion and dominance of 459 460 MR-MT28.

461

462 While the molecular mechanism underlying *B. pertussis* vaccine escape remains 463 unclear, three antigen genes have been implicated in this phenomenon: 464 autotransporters genes brkA and vag8, and surface protein filamentous hemagglutinin gene *fhaB*.<sup>30–33</sup> Intriguingly, all three genes were up-regulated in MR-MT28 compared 465 with *ptxP3*-other strains. This, together with upreguation of Ptx encoding genes and 466 467 other unidentified factors, may contribute to its enhanced vaccine escape. Despite the 468 capacity to infect vaccinated individuals, clinical symptoms of MR-MT28 infection 469 appear to be mild. This suggests that while the vaccine may not entirely prevent 470 infection, it can attenuate clinical symptoms, a phenomenon also observed in other pathogens such as SARS-CoV-2.34 471

472

473 By integrating public data and 11 newly sequenced genomes from Beijing and 474 Guangdong strains collected after 2019, our results showed the domestic spread and 475 colonization of MR-MT28. Newly sequenced strains were randomly selected, and no 476 information including subtyping and antimicrobial resistance was known in advance. 477 Notably, a surprisingly high proportion of these strains (Beijing: 5/8, Guangdong: 2/3) 478 were MR-MT28, suggesting that MR-MT28 may have cryptically dominated 479 infections in these regions, like in Shanghai, but had not been identified due to limited 480 surveillance and analysis or associated with their milder clinical symptoms. In 481 addition to the expansion in China, MR-MT28 potentially has a high global spread 482 risk because its consistent ptxP3 allele and epidemiology across many counties. Given 483 its resistance to first-line drugs and potentially competitive advantages, MR-MT28 484 warrants comprehensively global surveillance and research efforts.

485

486 Extremely high prevalence of MRBP indicates that macrolides are no longer suitable 487 as first-line drugs for pertussis treatment in Shanghai and even China. 488 Sulfamethoxazole/trimethoprim could be a good replacement because all MRBP 489 strains were susceptible to it. While traditional drug susceptibility testing replies on 490 strain culture and is time-consuming, PCR testing targeting specific mutations such as 491 23S rRNA A2047G mutation carried by all MRBP strains, offers a supplement or 492 alternative. For MR-MT28, BP0685 G15951A mutation or prn150 are candidate 493 targets, though the latter may present some problems (one non-MR-MT28 strains

494 carried *prn150*, 26% MR-MT28 were predicted PRN-deficient).

495

496 Our studies have several limitations. First, most samples used for strain culture were 497 obtained after patients had received antimicrobial treatment, which may introduce bias 498 to the incidence of MRBP. However, this issue is common and remained consistent 499 throughout the sampling period. Second, due to the unavailability of Ptx antibodies in China, we could only investigate the expression levels. Nonetheless, high expression 500 501 does not necessarily correspond to increased Ptx production and virulence. Finally, 502 while we provided evidence of domestic spread and colonization of MR-MT28, due to 503 the small sample size except Shanghai, the incidence of MR-MT28 in China requires 504 further evaluation based on more samples, especially samples collected 505 post-COVID-19.

506

507 In conclusion, a novel *B. pertussis ptxP3*-linage clone, MR-MT28, has emerged and 508 dominated infections in Shanghai post-COVID-19. MR-MT28 may have competitive 509 advantages due to antimicrobial resistance, enhanced vaccine escape, increased 510 opportunities for transmission and transmissibility, which drove the pertussis upsurge, 511 age shift, vaccine escape and sharp increase in MRBP prevalence. We reconstructed 512 the evolutionary history of MR-MT28 and demonstrated its domestic spread and 513 colonization. This novel clone potentially has a higher global spread risk because its 514 consistent ptxP3 allele and epidemiology across many counties, which warrants 515 further comprehensive global surveillance and research efforts. Macrolides may no 516 longer be suitable as first-line drugs for pertussis treatment in China due to the extremely high prevalence of MRBP post-COVID-19. 517

518

#### 519 **Contributors**

520 CW, PF, CY, and LG contributed to the conception of this project. PF and GY were 521 responsible for collection of clinical and laboratory data. WC and PF performed 522 clinical and laboratory data analysis. CY and LX performed bioinformatics analysis of 523 whole genome sequence data. JQ, JZ and YL participated the genome preparision and 524 qPCR. JQ, YK, SQ, SW, JZ and YL participated in the experiments. CY and PF 525 prepared the manuscript. All authors contributed to the interpretation of results and 526 critical review of the manuscript.

527

#### 528 **Declaration of interests**

- 529 We declare no competing interests.
- 530

#### 531 Acknowledgments

This work was supported by grants from the National Key Research and Development Program of China (2021YFC2701800 and 2022YFC2304700), National Natural Science Foundation of China (82202567 and 32270003), Youth Innovation Promotion Association, Chinese Academy of Sciences (2022278), and Shanghai Rising-Star Program (23QA1410500), and Shanghai municipal three-year action plan for strengthening the construction of the public health system (2023-2025) GWVI-2.1.2.

538	Refer	ences
539	1	Kapil P, Merkel TJ. Pertussis vaccines and protective immunity. Curr Opin Immunol. 2019;
540		<b>59</b> : 72–8.
541	2	Mooi FR, Van Der Maas NAT, De Melker HE. Pertussis resurgence: Waning immunity and
542		pathogen adaptation - Two sides of the same coin. Epidemiol Infect. 2014; 142.
543	3	Sealey KL, Belcher T, Preston A. Bordetella pertussis epidemiology and evolution in the
544		light of pertussis resurgence. Infection, Genetics and Evolution. 2016; 40: 136-43.
545	4	De Cellès MD, Magpantay FMG, King AA, Rohani P. The impact of past vaccination
546		coverage and immunity on pertussis resurgence. Sci Transl Med 2018; 10.
547	5	Clark TA. Changing pertussis epidemiology: Everything old is new again. Journal of
548		Infectious Diseases. 2014; 209.
549	6	Yeung KHT, Duclos P, Nelson EAS, Hutubessy RCW. An update of the global burden of
550		pertussis in children younger than 5 years: a modelling study. <i>Lancet Infect Dis</i> 2017; <b>17</b> :
551		974–80.
552	7	Li L, Deng J, Ma X, et al. High prevalence of macrolide-resistant bordetella pertussis and
553		ptxP1 Genotype, Mainland China, 2014-2016. Emerg Infect Dis. 2019; 25.
554	8	McIntyre PB, Best E, Byrnes CA, Sinclair O, Trenholme A, Grant CC. Pertussis deaths in
555		New Zealand without community transmission—an infant immunity gap? Lancet Reg
556		Health West Pac. 2023; <b>37</b> .
557	9	Cohen R, Ashman M, Taha MK, et al. Pediatric Infectious Disease Group (GPIP) position
558		paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the
559		immunity gap? Infect Dis Now. 2021; 51.
560	10	Mengyang G, Yahong H, Qinghong M, Wei S, Kaihu Y. Resurgence and atypical patterns
561		of pertussis in China. Journal of Infection. 2024; 88.
562	11	Overview of the China national epidemic situation of notifiable infectious diseases in
563		February 2024.
564		https://www.ndcpa.gov.cn/jbkzzx/c100016/second/content/content_176998215784665088
565		0.html.
566	12	Reported cases of whooping cough by month in 2023 and 2024 in the Netherlands.
567		https://www.rivm.nl/en/whooping-cough/current-figures-on-whooping-cough-in-
568		netherlands.
569	13	Confirmed cases of pertussis in England by month.
570		https://www.gov.uk/government/publications/pertussis-epidemiology-in-england-
571		2024/confirmed-cases-of-pertussis-in-england-by-month.
572	14	Dalby T. Clarifying pertussis in Denmark. Lancet Infect Dis. 2024; 24.
573	15	Bart MJ, Harris SR, Advani A, et al. Global population structure and evolution of
574		Bordetella pertussis and their relationship with vaccination. <i>mBio</i> 2014; <b>5</b> .
575	16	Mooi FR, Van Loo IHM, Van Gent M, et al. Bordetella pertussis strains with increased
576		toxin production associated with pertussis resurgence. Emerg Infect Dis 2009; 15.
577	17	Ma L, Caulfield A, Dewan KK, Harvill ET. Pertactin-deficient Bordetella pertussis,
578		vaccine-driven evolution, and reemergence of pertussis. Emerg Infect Dis 2021; 27.
579	18	Feng Y, Chiu C-H, Heininger U, et al. Emerging macrolide resistance in Bordetella
580		pertussis in mainland China: Findings and warning from the global pertussis initiative. The
581		Lancet Regional Health-Western Pacific 2021; 8: 98.

582	19	Xu Y, Zhang L, Tan Y, Wang L, Zhang S, Wang J. Genetic diversity and population
583		dynamics of Bordetella pertussis in China between 1950-2007. Vaccine 2015; 33.
584	20	Yao K, Deng J, Ma X, et al. The epidemic of erythromycin-resistant Bordetella pertussis
585		with limited genome variation associated with pertussis resurgence in China. Expert Rev
586		Vaccines 2020; 19: 1093–9.
587	21	Wu X, Du Q, Li D, et al. A Cross-Sectional Study Revealing the Emergence of
588		Erythromycin-Resistant Bordetella pertussis Carrying ptxP3 Alleles in China. Front
589		<i>Microbiol</i> 2022; <b>13</b> .
590	22	Fu P, Zhou J, Meng J, et al. Emergence and spread of MT28 ptxP3 allele
591		macrolide-resistant Bordetella pertussis from 2021 to 2022 in China. International Journal
592		of Infectious Diseases 2023; 128: 205–11.
593	23	Fu P, Zhou J, Yang C, et al. Molecular Evolution and Increasing Macrolide Resistance of
594		Bordetella pertussis, Shanghai, China, 2016–2022. Emerg Infect Dis 2024; 30: 29.
595	24	Hu Y and ZL and SW and MQ and YL and YY and HL and WY and ML and YK.
596		Bordetella Pertussis Carrying ptxP3-Allele Spread Rapidly with its Erythromycin
597		Resistance Acquired in China. SSRN 2023.
598	25	Ning GJ, GY, WD, LJ, LY, SZ, & YZ. Epidemiology of pertussis in China, 2011–2017.
599		Chinese Journal of Vaccines and Immunization 2018; 24: 264–7.
600	26	Yang C, Li Y, Jiang M, et al. Outbreak dynamics of foodborne pathogen Vibrio
601		parahaemolyticus over a seventeen year period implies hidden reservoirs. Nat Microbiol
602		2022; 7: 1221–9.
603	27	Bridel S, Bouchez V, Brancotte B, et al. A comprehensive resource for Bordetella genomic
604		epidemiology and biodiversity studies. Nat Commun 2022; 13.
605	28	Schouls LM, Van Der Heide HGJ, Vauterin L, Vauterin P, Mooi FR. Multiple-locus
606		variable-number tandem repeat analysis of Dutch Bordetella pertussis strains reveals rapid
607		genetic changes with clonal expansion during the late 1990s. J Bacteriol 2004; 186.
608	29	Wiley KE, Zuo Y, Macartney KK, McIntyre PB. Sources of pertussis infection in young
609		infants: A review of key evidence informing targeting of the cocoon strategy. Vaccine.
610		2013; <b>31</b> .
611	30	Fernandez RC, Weiss AA. Cloning and sequencing of a Bordetella pertussis serum
612		resistance locus. Infect Immun 1994; 62.
613	31	Berggård K, Johnsson E, Mooi FR, Lindahl G. Bordetella pertussis binds the human
614		complement regulator C4BP: Role of filamentous hemagglutinin. Infect Immun 1997; 65.
615	32	Marr N, Shah NR, Lee R, Kim EJ, Fernandez RC. Bordetella pertussis autotransporter
616		Vag8 binds human C1 esterase inhibitor and confers serum resistance. PLoS One 2011; 6.
617	33	Jongerius I, Schuijt TJ, Mooi FR, Pinelli E. Complement evasion by Bordetella pertussis:
618		implications for improving current vaccines. J Mol Med. 2015; 93.
619	34	Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2
620		vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths
621		following a nationwide vaccination campaign in Israel: an observational study using
622		national surveillance data. The Lancet 2021; 397.
623		
624		
625		

	Total	ptxP1	MR-MT28	MS-MT28	ptxP3-other	<i>p</i> -value (MR-MT28 vs others)
Age						
0-1 y	458 (68%)	247 (83%)	47 (25%)	21 (100%)	143 (87%)	All pairs p<0.01
>1-3y	48 (7%)	20 (7%)	16 (8%)	/	12 (7%)	
4-6y	77 (11%)	17 (6%)	56 (30%)	/	4 (2%)	All pairs $p < 0.01$
7-10y	80 (12%)	13 (4%)	61 (32%)	/	6 (4%)	All pairs $p < 0.01$
>10y	9 (1%)	/	9 (5%)	/	/	
Gender						
Female	310 (46%)	136 (45%)	87 (46%)	8 (38%)	79 (48%)	
Male	365 (54%)	163 (55%)	103 (54%)	13 (62%)	86 (52%)	
Vaccination	. ,			. ,	. ,	
Yes	284 (52%)	89 (39%)	150 (87%)	3 (21%)	42 (33%)	All pairs $p < 0.01$
No	262 (48%)	142 (61%)	22 (13%)	11 (79%)	87 (67%)	All pairs $p < 0.01$
<b>Clinical characteristics</b>	. ,				. ,	
Spasmodic cough	593 (87%)	283 (94%)	136 (72%)	20 (95%)	154 (93%)	All pairs $p < 0.05$
Paroxysmal cough	565 (83%)	252 (83%)	159 (84%)	19 (90%)	135 (82%)	
Cockcrow-like cough	123 (18%)	60 (20%)	29 (15%)	3 (14%)	31 (19%)	
Wheeze	147 (22%)	81 (27%)	14 (7%)	11 (52%)	41 (25%)	All pairs p<0.01
Sputum	446 (66%)	199 (66%)	108 (57%)	20 (95%)	119 (72%)	All pairs $p < 0.05$
Facial blushing	273 (40%)	135 (45%)	33 (17%)	12 (57%)	93 (56%)	All pairs $p < 0.01$
Post-tussive vomiting	202 (30%)	101 (33%)	32 (17%)	8 (38%)	61 (37%)	All pairs $p < 0.05$
Runny nose	251 (37%)	116 (38%)	63 (33%)	10 (48%)	62 (38%)	• •
Fever history	72 (11%)	38 (13%)	18 (9%)	3 (14%)	13 (8%)	
Apnea	4 (1%)	2 (1%)	1 (1%)	0 (0%)	1 (1%)	
Hospitalization	138 (20%)	81 (27%)	12 (6%)	8 (38%)	37 (22%)	All pairs p<0.01
Hospitalization days	6 (5-10)	6 (5-10)	4 (1-7)	6 (5-10)	7 (5-10)	<i>ptxP1</i> : <i>p</i> <0.01 <i>ptxP3</i> -other: <i>p</i> <0.05
Chest computed tomogr	raphy (CT)					
Normal	159 (23%)	64 (21%)	59 (31%)	2 (10%)	34 (21%)	All pairs p<0.05
Moderate (bronchitis)	294 (43%)	119 (39%)	90 (47%)	7 (33%)	78 (47%)	
(bronchopneumonia or	225 (33%)	119 (39%)	41 (22%)	12 (57%)	53 (32%)	All pairs p<0.05
pneumonia)						* -
Laboratory testing						$= t = D I_1 = c = c = 0.01$
Abnormal CRP	78 (12%)	25 (8%)	37 (20%)	1 (5%)	15 (9%)	ptxP1: p<0.01 ptxP3-other: p<0.01
Abnormal WBC	380 (58%)	177 (61%)	86 (47%)	15 (71%)	102 (64%)	All pairs $p < 0.05$

# 626 Table 1. Demographic, clinical and laboratory characteristics of children patients.

627 Data are n (%) or median (IQR). CRP: C-reactive protein, WBC: white blood cell

628

629

## 630 Figure legends

Figure 1. Pertussis epidemic dynamics in Shanghai, China between 2016 and 2024. (A) Monthly number of culture-positive children patients and annually proportions of MRBP/*ptxP3*/*ptxP3*-MRBP infection, older children (aged >1y) and vaccinated populations. Data from 2020 was not analysed due to insufficient sample size (n=1). (B) Transition of pertussis epidemiology from pre- to post-COVID-19 stage.

637

Figure 2. Phylogenomic and epidemiological characteristics of MR-MT28. (A)
Phylogenetic tree, source and antigen gene alleles of Shanghai strains. (B) Temporal
dynamics and age and vaccination composition of patients of different lineages/clones.
(C) Proportion of genomically clustered strains.

642

Figure 3. Transcriptomic (RNA-seq) and qPCR analyses of gene expression. (A,B) Volcano plot showing differentially expressed genes (left) and pathways (right). (C) Expression levels of seven antigen genes detected by qPCR. \*\*: p<0.01, NS: not significant.

647

**Figure 4. MR-MT28 in China and global context.** (A) Phylogenic tree of Shanghai and global strains. The colors of outer ring indicated geographical regions. MR-MT28 and MS-MT28 were highlighted with red and orange backgrounds. (B) Maximum clade credibility tree of MT28 clone and geographical distribution of MR-MT28 in China. Branch colors indicated geographical regions. Key time points and genetic events were indicated by arrows and triangles. (C) Effective population size dynamics of MT28 clone inferred by Bayesian Skygrid analysis.







